We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

24 hedge funds and large institutions have $3.19M invested in Eiger BioPharmaceuticals, Inc. in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 15 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% less capital invested

Capital invested by funds: $4.17M → $3.19M (-$977K)

44% less funds holding

Funds holding: 43 → 24 (-19)

80% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 15

86% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 21

Holders
24
Holders Change
-19
Holders Change %
-44.19%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
15
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SAM
Simplify Asset Management
Nevada
+$559K
2
AWP
Accretive Wealth Partners
New Jersey
+$392K
3
TRCT
Tower Research Capital (TRC)
New York
+$8.31K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$1.97K
5
Osaic Holdings
Osaic Holdings
Arizona
+$453

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$250K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$202K
3
State Street
State Street
Massachusetts
-$33K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$29.4K
5
Northern Trust
Northern Trust
Illinois
-$25.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
– -$25.2K -3,744 Closed
Millennium Management
27
Millennium Management
New York
– -$18.2K -2,705 Closed
SFA
28
Sequoia Financial Advisors
Ohio
– -$14.1K -2,100 Closed
TSS
29
Two Sigma Securities
New York
– -$12.8K -1,907 Closed
Verition Fund Management
30
Verition Fund Management
Connecticut
– -$12.2K -1,806 Closed
TAM
31
Tocqueville Asset Management
New York
– -$8.38K -1,244 Closed
Charles Schwab
32
Charles Schwab
California
– -$7.51K -1,115 Closed
TC
33
TownSquare Capital
Utah
– -$7.28K -1,081 Closed
Jane Street
34
Jane Street
New York
– -$6.62K -984 Closed
HF
35
HRT Financial
New York
– -$6K -971 Closed
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
– -$5.73K -850 Closed
Bank of New York Mellon
37
Bank of New York Mellon
New York
– -$4.63K -688 Closed
EGM
38
Engineers Gate Manager
New York
– -$3.25K -483 Closed
Simplex Trading
39
Simplex Trading
Illinois
– -$2K -437 Closed
Prudential Financial
40
Prudential Financial
New Jersey
– -$2.69K -400 Closed
Citadel Advisors
41
Citadel Advisors
Florida
– -$2.25K -334 Closed
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
– -$522 -77 Closed
SIS
43
Sound Income Strategies
Florida
– -$90 -13 Closed
PCTC
44
Perkins Coie Trust Company
Washington
– -$39 -6 Closed
1
2

EIGR Hedge Fund Activity: Q1 2024 in Review

24 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2024, worth a combined $3.19M — down 23% from $4.17M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of EIGR and 3 opened new positions — a net loss of 18 holders — while 15 trimmed existing stakes and 3 added.

The largest buyer was Simplify Asset Management, opening a new position worth an estimated $559K. The largest seller was 683 Capital Management, cutting an estimated $250K.

  • 24 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2024, down from 43 in Q4 2023.
  • Funds reported $3.19M of Eiger BioPharmaceuticals, Inc. stock for Q1 2024, down 23% quarter-over-quarter.
  • 3 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2024 and 21 closed out, a net change of -18 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2024 was Simplify Asset Management, an estimated $559K added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2024 was 683 Capital Management, an estimated $250K sold.

Based on aggregated 13F filings for Q1 2024.